A 72-year-old Indian man with a 10-year history of dry age-related macular degeneration presents for routine follow-up. He reports no change in vision over the past 3 months. Visual acuity is 6/18 bilaterally. Fundoscopy shows multiple drusen, retinal pigment epithelial atrophy, and a well-demarcated area of geographic atrophy (GA) measuring 2 disc diameters in the right macula. OCT confirms loss of the photoreceptor layer over the atrophic area. The left eye shows early drusen without atrophy. What is the most appropriate management strategy for this patient?

Explanation

## Clinical Diagnosis **Key Point:** This patient has **dry AMD with geographic atrophy (GA)**—the advanced stage of dry AMD characterized by irreversible loss of photoreceptors, retinal pigment epithelium (RPE), and choriocapillaris over a well-demarcated area. ## Pathophysiology of Geographic Atrophy 1. Drusen accumulation → RPE dysfunction 2. Oxidative stress and inflammation → RPE cell death 3. Photoreceptor loss and choriocapillaris atrophy → irreversible vision loss 4. GA is **non-neovascular** (no CNV, no hemorrhage, no exudates) **High-Yield:** GA is the end-stage of dry AMD and represents irreversible photoreceptor loss. Current management is **supportive and preventive**, not curative. ## Management of Geographic Atrophy ### Why AREDS2 Supplementation Is Correct **Clinical Pearl:** The Age-Related Eye Disease Study (AREDS2) demonstrated that oral antioxidant supplementation (vitamins C, E, lutein, zeaxanthin, zinc) slows the progression of dry AMD and reduces the risk of CNV development by ~25% in intermediate-to-advanced disease. **Mechanism:** - Antioxidants reduce oxidative stress in the retina - Lutein and zeaxanthin accumulate in the macula and filter blue light - Zinc supports RPE function and photoreceptor health - These agents slow (but do not reverse) GA progression **Additional Management:** - **Low-vision counseling and aids:** Magnifying glasses, high-contrast reading materials, bright lighting - **Lifestyle modification:** Smoking cessation (major risk factor), UV protection, Mediterranean diet - **Monitoring:** Regular OCT and visual acuity assessment to detect CNV conversion (10–15% risk per year) ## Why Other Options Are Incorrect | Option | Why Incorrect | |--------|---------------| | **Intravitreal aflibercept** | Anti-VEGF agents are for **wet AMD (CNV)**, not dry AMD or GA. This patient has no CNV, hemorrhage, or exudates. Anti-VEGF is ineffective for GA. | | **Laser ablation of GA** | Laser causes further photoreceptor damage and is contraindicated. GA is already atrophic (dead tissue); laser will not restore vision. | | **Vitreoretinal surgery for drusen** | Drusen removal surgery is not standard of care and carries high risk of iatrogenic damage. Drusen are intracellular lipid deposits; surgical removal is not feasible or beneficial. | **Mnemonic:** **Dry AMD (GA) = AREDS2 + Monitoring + Low-vision aids.** Wet AMD (CNV) = Anti-VEGF. Do NOT confuse the two. ```mermaid flowchart TD A[Age-Related Macular Degeneration]:::outcome --> B{Wet or Dry?}:::decision B -->|Wet AMD<br/>CNV present| C[Anti-VEGF therapy<br/>bevacizumab/ranibizumab]:::action B -->|Dry AMD<br/>No CNV| D{Stage?}:::decision D -->|Early/Intermediate| E[AREDS2 supplementation<br/>Lifestyle modification]:::action D -->|Advanced GA| F[AREDS2 supplementation<br/>Low-vision aids<br/>Monitor for CNV conversion]:::action C --> G[Monthly OCT monitoring]:::action E --> H[Annual fundoscopy]:::action F --> H ``` [cite:Parson's Diseases of the Eye 22e Ch 9; AREDS2 Study Group 2013]